Quest Diagnostics (DGX) Expected to Release Earnings on Thursday

Quest Diagnostics (NYSE:DGX) is anticipated to issue its Q2 2026 results before the market opens on Thursday, July 23rd. Analysts expect the company to post earnings of $2.81 per share and revenue of $2.9743 billion for the quarter. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:30 AM ET.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, April 21st. The medical research company reported $2.50 EPS for the quarter, topping the consensus estimate of $2.37 by $0.13. The company had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.83 billion. Quest Diagnostics had a return on equity of 15.60% and a net margin of 9.07%.The firm’s revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.94 earnings per share. On average, analysts expect Quest Diagnostics to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Quest Diagnostics Stock Performance

Shares of DGX opened at $201.64 on Thursday. Quest Diagnostics has a 12-month low of $165.19 and a 12-month high of $219.20. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.67. The firm has a market cap of $22.32 billion, a PE ratio of 22.28, a price-to-earnings-growth ratio of 2.45 and a beta of 0.58. The company’s 50 day simple moving average is $199.68 and its 200-day simple moving average is $195.79.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Investors of record on Wednesday, July 8th will be issued a dividend of $0.86 per share. The ex-dividend date of this dividend is Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.7%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 38.01%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Barclays lifted their target price on Quest Diagnostics from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Wednesday, April 22nd. Jefferies Financial Group reissued a “buy” rating and set a $225.00 price objective on shares of Quest Diagnostics in a report on Tuesday, April 21st. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Sunday. UBS Group increased their price target on shares of Quest Diagnostics from $210.00 to $220.00 and gave the company a “neutral” rating in a research report on Wednesday, April 22nd. Finally, Evercore set a $225.00 price objective on Quest Diagnostics in a research note on Tuesday, April 21st. Seven analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $217.17.

Insider Transactions at Quest Diagnostics

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the sale, the senior vice president directly owned 13,510 shares in the company, valued at $2,702,000. This represents a 37.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the sale, the chief executive officer directly owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is currently owned by insiders.

Institutional Trading of Quest Diagnostics

Several large investors have recently bought and sold shares of the company. Quattro Advisors LLC acquired a new stake in shares of Quest Diagnostics during the fourth quarter valued at about $25,000. DV Equities LLC bought a new stake in shares of Quest Diagnostics in the 4th quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd bought a new stake in Quest Diagnostics during the third quarter valued at $33,000. State of Wyoming raised its stake in Quest Diagnostics by 89.6% during the fourth quarter. State of Wyoming now owns 201 shares of the medical research company’s stock worth $35,000 after acquiring an additional 95 shares during the period. Finally, Quarry LP raised its position in shares of Quest Diagnostics by 156.0% during the 3rd quarter. Quarry LP now owns 279 shares of the medical research company’s stock worth $53,000 after purchasing an additional 170 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.